Ulgan Inan Sila, MD | |
1205 York Road, Suite #39, Lutherville, MD 21093-6211 | |
(410) 296-3113 | |
(410) 296-6170 |
Full Name | Ulgan Inan Sila |
---|---|
Gender | Female |
Speciality | Allergy & Immunology |
Location | 1205 York Road, Lutherville, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1629140785 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207K00000X | Allergy & Immunology | D0010425 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ulgan Inan Sila, MD 1205 York Road, Suite #39, Lutherville, MD 21093-6211 Ph: (410) 296-3113 | Ulgan Inan Sila, MD 1205 York Road, Suite #39, Lutherville, MD 21093-6211 Ph: (410) 296-3113 |
News Archive
SeraCare Life Sciences, a manufacturer of life sciences tools, bulk plasma, and quality controls for diagnostic companies and clinical laboratories, announced an expansion of its research and manufacturing facilities at its Milford, Massachusetts headquarters.
The International Osteoporosis Foundation (IOF) has awarded the IOF-Servier Young Investigator Research Grant to co-winners Dr. Frank DeVries, University of Utrecht, the Netherlands, and Dr. Davide Ruffoni, Institute for Biomechanics, ETH Zurich, Switzerland.
"There are three main options on the table" about what to do after the Millennium Development Goals expire in 2015, Leo Williams, chair of Beyond 2015, an international campaign that aims to "ensure that the process of developing a development framework is participatory, inclusive and responsive to those directly affected by poverty and injustice," writes in a post on the Guardian's "Poverty Matters Blog."
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today that it consummated its previously announced private placement to sell approximately $15.2 million of its units to several institutional investors, including the Special Situations Funds, for net proceeds of approximately $14.1 million after the deduction of offering expenses.
An international clinical trial has found that a new drug for Huntington disease is safe, and that treatment with the drug successfully lowers levels of the abnormal protein that causes the debilitating disease in patients.
› Verified 4 days ago